Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00665626 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
A Phase 2 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 219
- Enrollment target
NCT00665626 is a Phase 2 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 219 participants.
The verdict
NCT00665626, a Phase 2 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor, R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.
Interventions
- DRUG Placebo
- DRUG Fostamatinib disodium (R935788)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00665626
The ClinicalTrials.gov registry entry for NCT00665626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00665626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00665626 about?
NCT00665626 is a clinical study titled "Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)". The purpose of this study is to determine whether the Spleen Tyrosine Kinase (Syk) Inhibitor, R935788 (R788) at a dose of 100 mg, tablet, orally, twice-a-day is effective in the treatment of Rheumatoid Arthritis in patients who have 'failed' a biologic therapy.
What is the current status of trial NCT00665626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 219 participants. The study started on 2008-05. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00665626?
The interventions under investigation include: Placebo (DRUG), Fostamatinib disodium (R935788) (DRUG).
Who is sponsoring clinical trial NCT00665626?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.